Mesenchymal hamartoma of the liver (MHL) is a rare, benign hepatic tumor that primarily affects infants and young children, typically presenting within the first two years of life. Histologically, MHL is characterized by a mixture of mesenchymal stroma, bile ducts, and cystic spaces, often resulting in a multicystic or solid-cystic mass. The lesion is thought to arise from aberrant development of the portal tract mesenchyme, and some studies suggest a possible link to vascular anomalies or ischemic injury during hepatic development. Clinically, MHL may present as an asymptomatic abdominal mass or with symptoms such as abdominal distension, pain, or respiratory distress due to the mass effect. Imaging typically reveals a well-demarcated, cystic hepatic lesion, but definitive diagnosis requires histopathological confirmation. Complete surgical excision is the treatment of choice and is usually curative, with an excellent prognosis. However, rare cases of malignant transformation and recurrence have been reported, underscoring the importance of long-term follow-up.